Podcasts about Munster

In this episode of Friday Night Beers, Tom & Vince try a beer called Zombie Dust. This beer comes from 3 Floyds Brewing in Munster, Indiana. The hosts drink it and somehow compare it to things like Mötley Crüe, Our Flag Means Death, The Wolf of Wall Street, movie role swaps, Martin Scorsese, Al Pacino and more. At the end, they rate this beer on a unique 1-5 scale.  VINCE: 4 / 5 VincesTOM: 4.75 / 5 TomsInstagram: @friday.night.beers Twitter: @fnb_pod Email: friday.night.beerspodcast@gmail.com Theme music by Billy Hansa. Subscribe, rate and review the podcast on Apple, Spotify or wherever you find your podcasts!

Please join author Subodh Verma and Guest Editor Christopher Granger as they discuss the article "Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-host. I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr. Peder Myhre: And I'm Dr. Peder Myhre, social media editor and doctor at Akershus University Hospital at University of Oslo in Norway. Dr. Carolyn Lam: Peder, I am so excited to be discussing this issue. So many great articles and a feature discussion coming up on the SGLT2 inhibitor, empagliflozin. And do you think it's got effects on left ventricular remodeling in people without diabetes? Very interesting question. Dr. Peder Myhre: That is so interesting, Carolyn. I can't wait to hear this discussion. Dr. Carolyn Lam: Yep, I agree, but we got to wait till we discuss the other papers in today's issue. I want to go first. So we know that non-vitamin K oral anticoagulants, or NOACs, they've become the standard therapy for preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation. But, what is the effectiveness and safety of NOACs in patients on dialysis? That is hemodialysis. The AXADIA-AFNET 8 study sought to test the hypothesis that apixaban would be non-inferior to vitamin K antagonists in these very patients undergoing hemodialysis. Dr. Peder Myhre: Oh wow. This is really a gap of knowledge that we've been waiting to hear more about. NOACs in patients with hemodialysis. Tell us about this trial, Carolyn. Dr. Carolyn Lam: Sure. So this is from corresponding author, Dr. Reinecke, and colleagues, from University of Munster in Germany. And it's an investigator initiated prospective randomized open-blinded outcome assessment of 97 patients with atrial fibrillation on chronic hemodialysis randomized to either apixaban 2.5 mg BID, or a vitamin K antagonist, aiming for an INR between 2 and 3. Over a median follow-up time of 429 days for apixaban, and 506 days for the vitamin K antagonist, the composite primary safety outcome of first, major bleeding, clinically relevant, non-major bleeding, or all cause death, occurred in 46% of patients on apixaban, and 51% of patients on the vitamin K antagonist. That would be a hazard ratio of 0.91, with a p for non-inferiority being 0.157. How about the primary efficacy outcome? While this was a composite of ischemic stroke, all cause death, myocardial infarction, or deep vein thrombosis, and/or pulmonary embolism, and that occurred in 21% of patients on apixaban and 31% of patients on the vitamin K antagonists. Again, no difference when there was testing. So, in summary, Peder, there were no differences in the safety or efficacy observed between apixaban and vitamin K antagonists in patients with atrial fibrillation on chronic hemodialysis. Of note, however, even receiving oral anticoagulations, these patients remain at very high risk of cardiovascular events. So these data really support the consideration of apixaban for prevention of cardiovascular complications in patients with atrial fibrillation on chronic hemodialysis, but larger studies are definitely needed. Dr. Peder Myhre: Oh wow, Carolyn, that is so clinically relevant. And the next paper is also a clinically relevant paper. And it comes to us from the SPRINT authors. And to remind you, the SPRINT study was a study of intensive systolic blood pressure lowering compared to standard blood pressure lowering. And the results demonstrated that there was a robust reduction in both heart failure endpoints and all cause mortality. And in this sub-study that comes to us from corresponding author Jarett Berry from University of Texas Tyler School of Medicine, these authors look at the mechanisms through which intensive blood pressure lowering reduces the risk of these endpoints. And given the important role of cardiac injury and neurohormonal activation in the pathways leading from hypertension to heart failure, and strong association that has been observed between hypertension and levels of cardiac troponin and NT-proBNP, the authors hypothesized that intensive systolic blood pressure lowering would decrease levels of high sensitivity cardiac troponin T and NT-proBNP. Dr. Carolyn Lam: Cool. That's interesting. So how did they do this, and what did they find? Dr. Peder Myhre: So, as expected, Carolyn, the authors found that increases in troponin and NT-proBNP from baseline to 1 year were associated with a higher risk of heart failure and death. And there were really no significant interaction by treatment assignment. But let's look at the changes in troponin. And these results showed that randomization to intensive blood pressure lowering versus standard blood pressure lowering resulted in a significant 3% increase in cardiac troponin T level over 1 year follow up, and a higher proportion of participants with more than 50% increase, and that's with an odds ratio of 1.47. And Carolyn, in contrast, NT-proBNP decreased by 10% in intensive blood pressure arm. And these patients had substantially lower probability of increasing more than 50% in NT-proBNP, with an odds ratio of 0.57 compared to the standard arm. And now, to the most interesting part of this analysis, Carolyn, the association of randomized treatment assignment on changes in troponin was completely attenuated after accounting for changes in eGFR during the follow up, whereas the association of treatment with NT-proBNP changes were completely attenuated after adjusting for changes in systolic blood pressure. So Carolyn, the authors highlight in their discussion the importance of non-cardiac factors influencing variation in cardiac biomarkers, and raise questions about the potential role of cardiac troponin T as a surrogate marker for heart failure or death in blood pressure lowering studies. Dr. Carolyn Lam: Wow, very interesting. Thanks, Peder. Can I tell you now about a preclinical study? Very interesting, because it shows that cardiac inflammation and hypertrophy are regulated by a heart-brain interaction. Dr. Peder Myhre: Wow, Carolyn, a heart-brain interaction. I'm excited to hear more about this. Please explain. Dr. Carolyn Lam: I'd love to, but first some background. Interleukin-1 beta, now that is a pro-inflammatory cytokine that causes cardiac hypertrophy and heart failure. I need to familiarize you with this, the nucleotide-binding domain leucine-rich containing family, pyrin domain-containing-3, NLRP3 for short, which is an inflammasome, which is a cytosolic multiprotein complex that mediates active interleukin-1 beta production. Okay? So you know these terms, and now I want to tell you about the study. This is an elegant series of experiments performed by co-corresponding authors, Dr. Higashikuni, from University of Tokyo, and Dr. Sata, from Tokushima University Graduate School of Medicine, and their colleagues. They first showed that genetic disruption of the NLRP3 inflammasome resulted in significant loss of interleukin-1 beta production, cardiac hypertrophy, and contractile function during pressure overload. Next, a bone marrow transplantation experiment revealed an essential role of NLRP3 inflammasome in cardiac non-immune cells in myocardial interleukin-1 beta production and the cardiac phenotype. It was extracellular ATP released from sympathetic nerve terminals that induced the hypertrophic changes of cardiac cells in an NLRP3 and interleukin-1 beta dependent manner in vitro. And finally, depletion of ATP release from sympathetic efferent nerves, or ablation of cardiac afferent nerves, or a lipophilic beta-blocker, all reduced cardiac extracellular ATP, and inhibited the NLRP3 inflammasome activation, the interleukin-1 beta production, and the adaptive cardiac hypertrophy during pressure overload. So all of this suggests that controlling the neuronal brain signals might have therapeutic potential for the treatment of hypertensive heart disease. Neat, huh? Dr. Peder Myhre: Oh, that is so interesting. The heart and brain interaction. And, Carolyn, we're going to stay in the field of preclinical science. And now we're going to talk about another field that is really interesting, and that is regeneration of cardiomyocytes. Because, Carolyn, developmental cardiac tissue holds remarkable capacity to regenerate after injury, and consists of regenerative mononuclear and deployed cardiomyocytes. Whether reprogramming metabolism promotes persistence of these regenerative mononuclear and deployed cardiomyocytes that enhance cardiac function in repair after injury is unknown. Therefore, these researcher, led by corresponding author, Mohsin Khan, from Temple University School of Medicine, investigated whether the RNA binding protein, LIN28a, which is a master regulator of cellular metabolism, plays a role in cardiac repair following injury. Dr. Carolyn Lam: Wow. That is always, always interesting, regeneration and repair following injury. So what did the authors find? Dr. Peder Myhre: Well, Carolyn, through a number of elegant experiments, the authors made the following key findings. For the first time, they documented a role for RNA binding protein LIN28A in regulating cardiomyocyte turnover in the postnatal and adult heart. And LIN28a overexpression promotes cardiomyocyte cell cycle activity during postnatal development and extends cardiac regenerative ability of the mammalian heart to postnatal day 7. And in the adult heart, the authors could demonstrate that LIN28a drives new myocyte formation, augmenting cardiac structure and function after myocardial injury. And Carolyn, I'm sure you're going to ask the clinical implications of this study. Dr. Carolyn Lam: Indeed. Dr. Peder Myhre: And that is that these results may suggest a novel translational role for LIN28a based strategy to replenish cardiomyocytes in the adult heart after injury. Dr. Carolyn Lam: Very nice, Peder. Thank you. Also in the issue is a Research Letter by Dr. Bick on interleukin-6 receptor polymorphism attenuates clonal hematopoiesis mediated coronary artery disease risk among many individuals in the UK Biobank. There's also Cardiology News by Tracy Hampton, where she highlights few really interesting things, like aging cardiomyocytes accumulate new genetic mutations that was published in Nature Aging, cytokines promote tissue repair after a heart attack in mice, and that was published in Science, and scientists identifying molecular alterations in a failing heart at a single cell resolution, which was published in Nature. Dr. Peder Myhre: And there are a couple of other papers also in this issue, Carolyn. And there's first, an exchange of letters by Drs. Halushka, Lu, and Mayr, regarding the article "Circulating MicroRNA-122-5p is Associated with a Lack of Improvement in Left Ventricular Function after TAVR and Regulates Viability of Cardiomyocytes Through Extracellular Vesicles." And finally, we have an "On My Mind" piece by doctors Monda and Limongelli entitled "An Integrated Sudden Cardiac Risk Prediction Model for Patients with Hypertrophic Cardiomyopathy." Dr. Carolyn Lam: Oh, nice. Nice full issue. Thank you, Peder. Let's go to our feature discussion now. Shall we? Dr. Peder Myhre: Let's go. Dr. Greg Hundley: Welcome listeners to this feature discussion on January 24th. And we have with us Dr. Subodh Verma, from St. Michael's University in Toronto, Canada. And a guest editor, Dr. Christopher Granger, from Duke University in Durham, North Carolina. Welcome gentlemen. Well, Subodh, we will start with you. Can you describe for us some of the background information that went into the preparation of your study, and what was the hypothesis that you wanted to address? Dr. Subodh Verma: First, my great pleasure to be here, and thank you very much for the opportunity to discuss this paper with your viewers. As you know, SGLT2 inhibitors have been truly transformative therapies. From a heart failure perspective, we know that they prevent incident heart failure in people with diabetes who have vascular disease or risk factors. They also have been shown to treat prevalent heart failure in people with heart failure and either a reduced, mildly reduced, or preserved ejection fraction independent of glycemic status. And really, these have been the basis of very strong recommendations to use these agents in the prevention of heart failure in people with diabetes, and also in the treatment of prevalent heart failure in people with and without diabetes. Now, the fact that these drugs have such broad effects in people with heart failure has led to a theory that maybe these drugs could be introduced earlier on in the natural history of heart failure in people who neither have diabetes nor have significant heart failure, the so-called sort of stage A or stage B patient. But there really have been no clinical trials evaluating this question. There've been a lot of translational randomized trials that have provided some mechanistic insights about LV remodeling in people with diabetes or in people with prevalent heart failure. And we hypothesized that maybe the first step to evaluate whether SGLT2 inhibitors may have favorable effects on cardiac remodeling in people without diabetes or without heart failure would be to conduct a randomized double-blind control trial looking at indices of left ventricular remodeling in a population that I've just described. Dr. Greg Hundley: Very nice, Subodh. So you've started us into your study design. Maybe describe that a little more fully, and then who was included in your study population? Dr. Subodh Verma: So EMPA-HEART 2 CardioLink was a multi-center double-blind placebo control randomized trial in which we studied the effects of empagliflozin, an SGLT2 inhibitor, at a dose of 10 mg per day versus placebo in people who did not have type 2 diabetes or significant heart failure. We included people who were adults between the age of 40 and 80 who met 1 of 2 entry criteria. Either they had to have one major criteria, which was an increase in left ventricular mass index by specific echo criteria or MRI criteria, or they could have increased LVH as identified by ECG or by intraventricular septal or posterior wall thickness. They could also get in if they had resistant hypertension, hypertension despite being on 3 antihypertensive agents, or the second strata was entry through 2 minor criteria, which included a history of myocardial infarction, a GFR between 30 or 60, or evidence of overweight or obesity. Dr. Greg Hundley: And how many subjects did you randomize? Dr. Subodh Verma: So we randomized, of the 318 that we screened, 169 were randomized to receive empagliflozin 10 mg or a placebo. Patients had a baseline cardiac MRI done, and then the exposure was 6 months. They had a follow-up MRI at the end of 6 months. And the primary outcome measure was a 6-month change in left ventricular mass index from baseline to 6 months between the two groups. Dr. Greg Hundley: Very nice. And so , Subodh, can you describe for us now, what did you find? What were your study results? Dr. Subodh Verma: So, first and foremost, what we found in terms of baseline characteristics was that we enrolled a population of people with a mean age of around 60 with a BMI of around 30 kg/m2, predominantly men, about 80% or so were men. These were patients who did not have significant heart failure. The NT-proBNP at baseline was around 50 pg/mL. The eGFR was around 80 mL/minute, and the vast majority of these patients actually had a history of hypertension. Of course, none of them had diabetes by definition. The hemoglobin A1C was around 5.8%. Now what we found was, despite the fact that we went after patients who we thought would be enriched for a baseline increase in LV mass indices, the baseline LV mass index was mildly elevated, was around 63 g/m2. And over the course of 6 months, we did not find any significant difference in terms of LV mass regression between the placebo and empagliflozin groups. In fact, the adjusted treatment effect was minus 0.30 g/m2, which was not statistically significant. No other differences were found in terms of other indices of a remodeling, including left ventricular and diastolic or end systolic volume indices or in terms of left ventricular ejection fraction. There was a 2% increase in ejection fraction, and the p-value for that was 0.07, but really was not statistically significant. Dr. Greg Hundley: And very nice. And realizing that women may have smaller LV masses, any stratified analysis that evaluated effects on men versus women? And then what about, perhaps in the higher quartile versus lower quartile, of age? Dr. Subodh Verma: Right. So, Greg, we actually did look at various subgroups and covariates, including gender, including age. And age or gender did not really influence the overall result that we obtained. There was really a neutral result in empagliflozin, irrespective of these 2 covariates. We also looked at baseline blood pressure, baseline NT-proBNP, LV mass indices, the presence or absence of heart failure, chronic kidney disease. So for the covariates that we have evaluated over a short term of 6 months in this relatively low risk population, we did not find any heterogeneity the result, per se. Dr. Greg Hundley: Very good. Well, Subodh, thank you so much for that beautiful presentation. And listeners, now we're going to turn to our guest editor, Dr. Chris Granger. And Chris is an expert in the field of heart failure. Also, a lot of familiarity with HFpEF, which sounds a little bit, we're looking at precursors. We don't have HFpEF yet, but maybe trying to inhibit this from happening using empagliflozin. How do you put these results in the context with other studies that have emphasized utilizing SGLT2 inhibitors in patients with sort of a preserved ejection fraction and absence of diabetes? Dr. Christopher Granger: Yeah. Well thanks, Greg. And again, congratulations, Subodh, to your study. And I think you framed some of the context here as these drugs, the SGLT2 inhibitors, as being transformative, which I think is exactly right. And it's such a fascinating story. Right? These drugs, which we thought originally, with their cause of glucose spilling in the urine, and a modest decrease in blood glucose, might have a role for modestly improving glucose control in diabetes. And low and behold, they've turned out to be one of the great stories I think in recent, across all of medicine, in terms of their consistent and substantial improving clinical outcomes for patients with heart failure, with diabetes and cardiovascular disease, and now even kidney protection, and much broader implications. And their well tolerated, and they don't have dose titration. So there's some practical appeal to this class of drugs in terms of their benefits, in terms of clinical outcomes. But we're left with having this amazing evidence-based generated without really understanding why are these drugs so effective? And what are they doing? And you've provided, I think, an important piece to the puzzle. We did have the data from patients with diabetes and heart failure, with diabetes and left ventricular hypertrophy, that there is a modest reduce in LV mass with SGLT2 inhibitors. And what you've shown is that for patients that with mild LVH, with risk for LVH, that we simply don't see a substantial reduction in LV mass with the use of these drugs. So I think that provides this evidence that that's not a major cause of benefit, at least in this earlier phase of development of heart failure. And I think it really underscores the fact that there's a lot of work to do still to understand. We know that the renal effects are obvious place that these drugs have such an important benefit. And then the linkage of renal disease and cardiac performance is one of the areas, I think, that's a very exciting aspect of a probable contribution of the mechanism of these drugs. But I think in the end, we're left with still not really understanding why these drugs are so beneficial. But understanding that, I think, will be important, both for opening new avenues of targeting pathways, as well as being able to tell the clinical community, okay, you have these important benefits, but people do want to also know why are we seeing these benefits. Dr. Greg Hundley: Very nice. Well, listeners, we're going to turn back to Dr. Verma here. Subodh, what do you see is the next study to be performed in this sphere of research? Dr. Subodh Verma: Well, first, my thanks to Professor Granger, Chris, for handling this paper and for his very thoughtful comments. And he's absolutely right. We have such wonderful clinical data, and these results, of course, should not in any way take away from the importance of using empagliflozin or other SGLT2 inhibitors in the prevention of heart failure in people with diabetes, or in the treatment of HFpEF or HFrEF. But we're struggling with trying to understand what is the dominant mechanism of action here. And, in the previous precursor to EMPA-HEART 2, we did EMPA-HEART 1 in people with diabetes, and we saw a modest effect that was statistically significant of reduction in LV mass index. And we did not see this, of course, in a lower risk population without diabetes. And that tells me that remodeling may be occurring to a modest effect, it may require a longer time to actually show its benefits, but that this is unlikely a dominant sort of mechanism through which these drugs are working. And I do share Chris's thoughts that one of the key mechanisms of benefit that needs to be further explored is looking at the renal cardiac axes. We know that these drugs are profoundly renal protective, and that the benefits may actually be secondary to improvements in renal hemodynamics, improvements in renal function. And I think that is a population that needs to be, that's a mechanism that needs to be studied further. So I think the next generation of translational mechanistic studies need to really tease out the renal cardiac axes, maybe tease out populations that are at risk but have more significant left ventricular hypertrophy, maybe evaluate patients for a longer duration of treatment, or select people who truly have significant hypertension at baseline. I think those are groups and questions that need further exploration. And, of course, the translational science needs to be also studied in the context of larger completed clinical trials, where biomarkers are currently available and they can be linked, of course, to the outcomes in those trials. So those are some of my thoughts as to where the field could move towards. Dr. Greg Hundley: Very nice. And Chris, do you have anything to add? Dr. Christopher Granger: Subodh, I think that was a great summary. And I might just make a comment on the other end of the spectrum. That is, we have these drugs and the evidence of their benefit, and yet they're grossly underused in the populations that have proven to have benefit. Now it takes some time to educate, to get people familiar with, and get them to integrate these treatments into practice, but there's an enormous opportunity, and I think there is a linkage here. I think when people understand the mechanism, and when they're thoughtful about how these drugs may be working, that that really helps to make the case that the drug should be used, and that people are on board with using them. So I think there's this linkage here, there's the need to both better understand mechanism, and there's the need to have systems of care where these treatments are integrated to provide the benefit that's been so clearly shown in the randomized trials. Dr. Greg Hundley: Very nice. Well, listeners, we want to thank Dr. Subodh Verma, from St. Michael's University in Toronto, and our guest editor, Dr. Chris Granger, from Duke University in Durham, North Carolina, for bringing this paper highlighting that among people with neither diabetes nor significant heart failure but with risk factors for adverse cardiac remodeling, that SGLT2 inhibition with empagliflozin did not, did not, result in a meaningful reduction in LV mass index after 6 months. Well, on behalf of Carolyn, Peder, and myself, we want to wish you a great week, and we will catch you next week on the run. This program is copyright of the American Heart Association 2023. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

Greg, Lindsay and Jason are in the House of Rugby studio to discuss Munster vs. Toulouse and Ireland's Six Nations squad announcement. They also cover the Champions Cup Last 16 draw and Pat sits down for a chat with Leinster and Ireland star Robbie Henshaw. (1:00) - Munster push Toulouse close (9:00) - Joey Carbery debate (13:30) - Robbie Henshaw interview (32:10) - Netflix documentary (35:00) - Leinster and Ulster collision course (66:00) - Women's Interpros

Munster and Ireland legend Alan Quinlan joins Ger & Shane on #OTBAM after a mixed weekend for the Irish sides in the weekend's European action. Catch OTB's sports breakfast show LIVE weekday mornings from 7:30am or just search for OTB AM and get the podcast on the OTB Sports app or wherever you listen to yours. SUBSCRIBE and FOLLOW the OTB AM podcast. #OTBAM is live weekday mornings from 7:30am across Off The Ball, in association with Gillette | #EffortlessFlow

Munster coach Niamh Briggs joins Ger & Shane on #OTBAM after Munster capped their Interprovincial Series win with a 50-24 victory over Connacht on Saturday. Catch OTB's sports breakfast show LIVE weekday mornings from 7:30am or just search for OTB AM and get the podcast on the OTB Sports app or wherever you listen to yours. SUBSCRIBE and FOLLOW the OTB AM podcast. #OTBAM is live weekday mornings from 7:30am across Off The Ball, in association with Gillette | #EffortlessFlow

Fergus McFadden joins Dave McIntyre after Munster earn a bonus point against Toulouse in France. McFadden touches on Munster's exciting future, the impact of the new coaching staff and Joey Carbery's response to being dropped by Ireland. With Vodafone Ireland #TeamOfUs

Jake is back with another episode of The JBSE, recorded from a pleasant sunny day in the garden! The chat starts with thoughts on the journey of the podcast, and how and why it's taken a while to find the voice of the pod. That transitions into thoughts on why the Detroit Lions Hard Knocks series is an awesome workout backdrop, and why habit-building feels so important for moving our lives in the direction we want, whether you're an athlete, podcaster, artist, parent, whatever! Finally, there's time to ponder on two Hurling matches this weekend, as underdogs Dunloy take on power-house Ballyhale in the Senior Hurling Club All-Ireland Final, and an evolving Tipperary team test themselves in the final of the Munster pre-season competition against burgeoning dynasty Limerick. Follow the JBSE on Instagram, Facebook and Twitter!

Hear from Munster Attack Coach Mike Prendergast and Jean Kleyn ahead of Toulouse v Munster as Stade Ernest-Wallon on Sunday (3.15pm Irish time).

On Wednesday's Rugby Daily, there's more positive news regarding RG Snyman at Munster. Another Connacht player has committed their future to the province. The Ireland u20 and France Six Nations squads have been revealed.

Today we're delighted to be joined by Irish legend CJ Stander as he takes us through the incredible highs and terrifying lows of his career which took him from Captaining South Africa U20's to becoming a legend in Ireland and Munster. After getting the lads thoughts on the controversial news surrounding Eddie Jones and Dave Rennie and having heard their theories around the England Six Nations squad coming and goings, we're treated to some of the greatest stories you'll ever hear as CJ relives his greatest moments. From coming out of retirement to play in a charity match and nearly killing one of the opposition, to revealing for the first time why he really retired so young, to reliving the moment he decided he turn his back on South Africa, plus the terrifying moment he nearly killed himself when his BBQ exploded, his thoughts on Leinster, his terrifying school initiation, his stand our Lions memories and two hilarious stories from his early days attempting to settle in at Munster plus much much more.... we've got it all, so sit back and enjoy. Hosted on Acast. See acast.com/privacy for more information.

BBC Sport journalist Tom English joined Will O'Callaghan to discuss what prospects face Munster's Ben Healy who was named in the Scotland squad on Tuesday, and who will join Edinburgh at the end of the season. Rugby with Vodafone Ireland | #TeamOfUs

We're changing things up slightly this week and getting some thoughts from the most important piece of the Munster family - the fans! MRSC member Ray O'Brien joins Quinny and Niamh to give us a view from the stands and then dive into what was an excellent weekend for both Munster senior sides. Get in contact on Twitter @rugbychannel15 or email therugbychannel@bauermedia.ie! Subscribe to The Rugby Channel for new episodes every week! #TheRed78

It was a good weekend for all the provinces bar Ulster and Alan Quinlan was in the #OTBAM studio to look back at the action. Catch OTB's sports breakfast show LIVE on weekday mornings from 7:30am or just search for OTB AM and get the podcast on the OTB Sports app or wherever you listen to yours. SUBSCRIBE & FOLLOW the OTB AM podcast. #OTBAM is live weekday mornings from 7:30 am across Off The Ball, in association with Gillette. | #EffortlessFlow

0:00 Huge merch announcement  6:00 Stephen Crichton to leave Penrith  19:45 Munster hits back at Wayne Bennett  25:49 Ponga to play 6 this year  47:27 Titans announce their spine 1:05:37 Peter Peters comments about Turbo 1:13:53 Kevin Walters potential contract extension  1:24:27 Can Sharks be the next powerhouse? 1:35:18 New NRL rule amendments  1:52:58 Will Dom Young stay at Newcastle + could a draft even up the comp? 2:08:22 Who would win: Roosters 2018/19 or Panthers 2021/22

Jason and Lindsay look back on all the Champions and Challenge Cup action, discuss Six Nations squad calls and chat with Mindset & Performance Coach, Brian Moylett. They discuss: (1:20) - Munster's win and big names dropped (12:00) - Ulster heartbreak (16:30) - Leinster win big, and Jamie Osborne praise (20:00) - Caelan Doris backed by rugby greats (30:15) - Connacht bash Brive (35:00) - Women's Interpro (41:45) - Owen Farrell - “Absolute disgrace” (44:00)- Eddie Jones' Australia job (50:00) Brian Moylett interview (63:10) - Six Nations squad shots

Bringing your Dog to the PubWhy is someone selling Gecko's on the street in Cork? We kick off 'Live Free In 23' 2 Munster players on the ladies team got engaged and the comments were nasty A.F. We had another 9 out of 10 on the 2 Grand Minute The man who talks to Turkeys And what have you only just realised? KC and Ross In The Morning, Corks No1 Morning Show IMRO Winner of Ireland's Best Breakfast Show 2021 and 2022 Hosted on Acast. See acast.com/privacy for more information.

Nathan Murphy was joined by Irish Grand Slam winner Fiona Hayes and journalist Rúaidhrí O'Connor on this week's edition of Monday Night Rugby. (01:00) Eddie Jones is back! Have Australia made the right call? (11:00) Munster's faith in youth is being rewarded. (28:00) Brilliant Leinster and the battle against complacency. (35:00) What's going on with Bundee Aki? (40:00) Ulster's ongoing misery. Rugby in association with Vodafone | #TeamOfUs

Leinster proved victorious against Connacht 38-10 as Munster kept Ulster scoreless finishing 34-0 in Round 1 of the Vodafone #Rugby #InterprovincialChampionship this weekend. We've got all the talking points from the weekends action as well as a new fun segment; #GuessTheAthlete Her Sport's rugby coverage is brought to you in partnership with Energia - think of the possibilities. Visit the website https://hersport.ie/ Check out the Her Sport channels Instagram - https://www.instagram.com/hersport.ie Facebook - https://www.facebook.com/HerSport.ie/ Twitter - https://twitter.com/HerSportDotIE About Her Sport: Her Sport is a media platform centred on bringing the latest Irish and international women's sports news. Her Sport aims to empower women in sport, inspire more female participation, increase opportunity and level the playing field for future generations. Our objective is to create real and tangible change. Contact us: hello@hersport.ie

Aisling O'Reilly caught up with Munster head coach Graham Rowntree as well as European debutant Roman Salanoa after their narrow 27-23 victory over Northampton Saints in Thomond Park. She also caught up with the Saints' Director of Rugby Phil Dowson and captain Lewis Ludlam as Munster moved into their top four of their Heineken Champions Cup group. Rugby on Off The Ball, brought to you by Vodafone Ireland | #TeamOfUs

On Friday's Rugby Daily Richie McCormack brings you all of the team news ahead of this weekend's European action and the Women's Interprovincial Championship encounters. Where's Conor Murray? That's the main takeaway from Munster's selection to face Northampton. Cian Healy will reach a significant landmark at Kingsholm. Ian Madigan is back from injury as Ulster seek an upset win away to La Rochelle. And Mack Hansen has a change of scenery in Connacht's Challenge Cup meeting with Brive.

La Rochelle head coach and Irish rugby legend Ronan O'Gara joined OTBAM this morning to talk about his media policies, whether or not he tried to persuade Brian O'Driscoll to join Munster back in the day and look back over his side's win over Toulouse. Catch OTB's sports breakfast show LIVE weekday mornings from 7:30am or just search for OTB AM and get the podcast on the OTB Sports app or wherever you listen to yours. SUBSCRIBE and FOLLOW the OTB AM podcast. #OTBAM is live weekday mornings from 7:30am across Off The Ball, in association with Gillette | #EffortlessFlow

Murray Kinsella joins Gavan Casey from London Stanstead on his way to La Rochelle for Ulster's pivotal European tie tomorrow. The lads discuss Conor Murray's omission from Munster's matchday 23 to face Northampton in Thomond Park on Saturday, the speed of Munster's training which The42's Murray witnessed first-hand on Tuesday, and Leinster and Connacht's paths to the next stages of their respective European competitions.

Former Ireland and Lions captain Brian O'Driscoll joined Nathan Murphy on Thursday's Off The Ball. (0:00-13:39) - Owen Farrell's suspension, changes in how high tackles are being punished. (13:39-18:06) - Giving references for teammates at disciplinary hearings. (18:06-22:35) - Beyond a World Cup quarter-final would be a bonus for England. (22:35-33:35) - Heineken Champions Cup preview. (33:35-36:38) - Ben Healy's move to Edinburgh. (36:38-end) - ROG tried to get me to sign for Munster in '06.

With nearly 130 caps for the Irish rugby team, a British and Irish Lion, Munster's all-time leading points scorer - Ronan O'Gara is one of Ireland's sporting icons. From Munster to France, to New Zealand and back now as coach of LaRochelle, O'Gara talks with great honestly and openness about his experiences and lessons learned from the many different professional coaching environments he's been a part of. (3.30) – A confidence player (11.11) – Good people make better players (17.00) – Consistent buy-in (24.24) – The importance of fun (35.07) – Developing personal relationships Similar to season 1, I've set up this podcast with a dual purpose in mind, firstly to provide some thoughtful debate for coaches, but I've also linked up with Recovery Haven in Tralee, who provide free cancer support services for the people of Kerry and beyond. If you found some value in the podcast, it would be great if you could donate any amount, no matter how small to Recovery Haven through the link here: https://bit.ly/3tfsxWw If you enjoyed this episode, click on the like button, share, leave a review and follow the podcast. My thanks also to PST Sport for their support with this project. Go to pstsport.com for world class delivery of all your artificial grass pitch needs. Thanks for listening.

jQuery(document).ready(function(){ cab.clickify(); }); Original Podcast with clickable words https://tinyurl.com/2nf7s3td Contact: irishlingos@gmail.com Wind forecast: great weather promised tomorrow. Fógra gaoithe: aimsir mhór geallta amárach. Met Éireann has warned that there may be power cuts and travel disruptions due to the high winds that are expected in parts of the country tomorrow. Tá foláireamh tugtha ag Met Éireann go mb'fhéidir go ngearrfaí an chumhacht agus go gcuirfí as do chúrsaí taisitil mar gheall ar an ngaoth mhór atá geallta in áiteanna sa tír amárach. The wind warning issued by the meteorologists has a yellow status and will apply, they say, between 5 o'clock tomorrow morning and 2 o'clock Friday morning. Stádas buí atá ag an bhfógra gaoithe atá eisithe ag na meitéareolaithe agus beidh feidhm leis, a deir siad, idir 5 a chlog ar maidin amárach agus 2 a chlog ar maidin Dé hAoine. The wind will come from the west and it will be strongest in the west of the country at the beginning of the day. Ón aird aniar a thiocfas an ghaoth agus is in iarthar na tíre is láidre a bheas sí i dtús an lae. It will be a showery day in the west, especially along the coast in the north- west. Déanfaidh sé lá scuabach san iarthar, go háirithe cois cósta san iarthuaisceart. Tomorrow evening the wind will be strongest in the east. Tráthnóna amárach is láidre a bheas an ghaoth san oirthear. It is said that there was never a rain without a shower and a whole other announcement has been issued for Munster this evening. Deirtear nach raibh fearthainn riamh gan a fras agus tá fógra eile ar fad eisithe i gcomhair Chúige Mumhan tráthnóna. It is a yellow warning of rain and wind that will apply between 6 o'clock in the evening and midnight. Fógra buí báistí agus gaoithe atá ann a mbeidh feidhm leis idir 6 a chlog tráthnóna agus an meán oíche. There will be heavy rain and a speed of up to 110 kilometers per hour could be under some of the sheets. Beidh báisteach throm ann agus d'fhéadfadh luas suas le 110 ciliméadar san uair a bheith faoi chuid de na siotaí. There might be flooding in places as well. B'fhéidir go mbeadh tuilte in áiteanna chomh maith. RTÉ News and Current Affairs Nuacht agus Cúrsaí Reatha RTÉ

On this week's episode we talk about the four men's games that took place: Munster vs Lions, Connacht vs Sharks, the Ospreys vs Leinster, and Benetton vs Ulster. We also talk about the Women's games: Munster vs Ulster and Leinster vs Ulster. We preview next weekend's European rounds and interpro games too. It's just Jeff and Owen this week as Tom is in hiding.

Hear from Munster Defence Coach Denis Leamy ahead of Munster v Northampton at Thomond Park on Saturday.

On May 15 1648, the same day Holland signed the Treaty of Munster ending its 80 year war with Spain, a Dutch canal board issued a bond of 1,000 Carolus guilders to a Mr Niclaes de Meijer of Utrecht promising to pay him 5 per interest in perpetuity. In the latest of our Long Time Shorts, Jonathan explains how that promise is still being kept 374 years later, what Mr de Meijer's bond might be worth today, and why the Dutch are so good (relatively speaking) at meeting their financial obligations. Lang leve Nederland!Presented by Jonathan Ford and Neil Collins.Produced and edited by Nick Hilton for Podot.In association with Briefcase.News Hosted on Acast. See acast.com/privacy for more information.

Joe Molloy was joined by Irish rugby legends Keith Wood and Gordon D'Arcy for this week's Wednesday Night Rugby. (01:00) Owen Farrell, 'tackle school' and rugby bans. (17:00) Munster open up to the media. (23:00) Players hoping to break in Andy Farrell's Ireland plans. (37:00) HCC preview: Gloucester-Leinster; Munster-Northampton; La Rochelle-Ulster Rugby in association with Vodafone | #TeamOfUs

Kenny Cunningham and Richie McCormack joined Joe Molloy on Tuesday evening's edition of The Newsround, which turned into Kenny's Film Club. #OTBNR with Gillette | #EffortlessFlow

On Tuesday's Rugby Daily, Richie McCormack brings you the latest on those Malcolm Marx links to Munster. There's bad news upon bad news for Ulster. We hear from Jenny Murphy ahead of Leinster's Women's Interprovincial Championship meeting with Munster. Plus England, Wales and Italy suffer injury blows ahead of the Six Nations.

Joe Molloy was joined on Monday Night Rugby by Irish Independent rugby writer Ruaidhri O'Connor and former Ireland international, and current Munster coach Fiona Hayes. (00:00-07:30) Munster crush Lions (07:30-21:00) Rowntree v Kimmage, Rugby's concussion problem, Munster's media relationship (21:00-23:00) Connacht sink Sharks (23:00-32:00) Leinster home and hosed, Ross Byrne for Ireland, Furlong is crucial to Ireland (32:00-38:00) Ulster problems, 'confidence is shot' (38:00-45:00) Owen Farrell tackle, speeding the game up, 'length of time in the stadium is crazy' (45:00-53:00) Women's inter-pros, 'great advertisement for women's rugby' Vodafone Ireland | #TeamOfUs

Ciarán Kennedy joins Murray Kinsella to discuss interesting team selections from Munster and the Sharks ahead of the URC weekend. There's also a chat about Ulster's massive game in Italy. And the lads discuss World Rugby's push to speed the game up. If you want to get access to the members rugby pods, head over to members.the42.ie

Munster and the IRFU have confirmed that out-half Ben Healy will leave the province at the end of this season to go to Edinburgh. Billy Holland and Cian Tracey joined Matt to discuss whether Ireland will regret losing the 23-year-old, and the prospect of facing him in the Six Nations. Catch the full chat by pressing the 'Play' button on this page.

Ger Gilroy and Shane Hannon of OTB AM were joined by Munster and Ireland legends, Ronan O'Gara and Alan Quinlan. Catch OTB's sports breakfast show LIVE weekday mornings from 7:30am or just search for OTB AM and get the podcast on the OTB Sports app or wherever you listen to yours. SUBSCRIBE and FOLLOW the OTB AM podcast. #OTBAM is live weekday mornings from 7:30am across Off The Ball, in association with Gillette | #EffortlessFlow

Rugby: Al vier Suid-Afrikaanse spanne in die Verenigde Rugby-kampioenskap speel die naweek oorsee. Die Bulle kom net ná halftien môreaand in Wallis teen die Dragons te staan, terwyl die Leeus en Munster mekaar terselfdertyd in Ierland pak. Nog 'n Ierse span, Connacht, verwelkom Saterdag die Haaie, terwyl die Stormers Sondag in Skotland teen Glasgow Warriors sal uitdraf. Die Stormers is tans tweede op die punteleer ná Leinster, met die Bulle vierde, die Haaie vyfde en die Leeus 11de. Die president van die Blou Bulle, Willem Strauss...

In your Thursday Rugby Daily, Richie McCormack brings you news of the Munster team to face the Emirates Lions. There's details of Jurie Roux's resignation from SA Rugby. Cheslin Kolbe is sticking with Toulon. And a Challenge Cup fixture next month will make history.

Neil Treacy is joined by Ireland and Leinster prop, and Tackle Your Feelings ambassador Andrew Porter from 36:30). We also look ahead to the upcoming Women's Interprovincial Series with Munster assistant Fiona Hayes, as well as look back on the big talking points of the last week in rugby.

Hear from Shane Daly and Forwards Coach Andi Kyriacou as Munster prepare for a vital URC clash against Lions at Musgrave Park on Friday night (7.35pm)

We discuss Munster's win over Ulster, and Leinster's win over Connacht while we also preview the week's action and talk about flyhalves.

Kenny Cunningham and Richie McCormack joined Joe Molloy for Wednesday's edition of The Newsround #OTBNR with Gillette | #EffortlessFlow

Joe Molloy was joined by former Leinster, Connacht and Harlequins player Andy Dunne to on Wednesday Night Rugby. (02:00) Munster's Ben Healy is on his way to Edinburgh (and the Scotland NT?) (16:00) With Carbery at #10, who will be Ireland's Six Nations back-up? (25:00) Jack Carty underwhelms as Leinster outdo "workman-like" Connacht. (34:00) 'Terrible, appalling, soft': Ulster have serious issues to address. Rugby in association with Vodafone | #TeamOfUs

On the first Rugby Daily of 2023 there is bad new regarding Jonathan Sexton's face. There's a positive update from Munster regarding RG Snyman. Siya Kolisi and Stuart Lancaster will be working together in Paris. And lots of Ireland's Six Nations opponents are picking up untimely injuries.

Greg O'Shea, Lindsay Peat and Jason Hennessy hand out their awards for the best players and moments in 2022, before previewing a huge year of rugby in 2023. Greg kicks House of Rugby off with a recap of the New Years inter-pros. (0:35) - Intro and inter-pros chat (6:00) - 2022 rugby awards (27:15) - 2023 rugby predictions.

Munster & Ireland legend Alan Quinlan joins Ger & Shane to react to the final interpro derbies of the URC regular season. Catch OTB's sports breakfast show LIVE weekday mornings from 7:30am or just search for OTB AM and get the podcast on the OTB Sports app or wherever you listen to yours. SUBSCRIBE and FOLLOW the OTB AM podcast. #OTBAM is live weekday mornings from 7:30am across Off The Ball, in association with Gillette | #EffortlessFlow

Munster & Ireland legend Alan Quinlan joins Mick McCarthy for a preview of the final interpros of the URC regular season, as Munster travel to Ulster while Leinster host Connacht on New Year's Day. With Vodafone Ireland | #TeamOfUs

It's episode 51 to close out 2022. As ever, Quinny & Niamh have all the breakdown from a festive clash with Leinster on St. Stephen's Day. (00:00-02:00) Quinny on dealing with being spotted in the crowd. (02:00-05:00) Fans on the pod? (05:00-07:30) Leinster 'different gravy'. (07:30-13:00) What do the fans think? (13:00-19:00) Half-back pressure. (19:00-22:00) Munster work-rate. (22:00-28:00) Crucial refereeing decisions. (28:00-30:00) Star of the week. (30:00-35:00) Ravenhill New Year's test. (35:00-38:00) Will Munster have a better 2023? Get in contact on Twitter @rugbychannel15 or email therugbychannel@bauermedia.ie! Subscribe to The Rugby Channel for new episodes every week! #TheRed78

Jason Hennessy and Lindsay Peat look back on the first of the festive inter-pros, and there are House of Rugby interviews with Jimmy O'Brien and Charles Piutau. (0:45) - Leinster get one over Munster (13:00) - Ulster survive Connacht comeback (22:10) - Part 2 of our Jimmy O'Brien interview (35:40) - Interview with Charles Piutau

On Friday's Rugby Daily, Richie McCormack brings you news of the Munster and Leinster teams that will line out on Stephen's Day at Thomond Park. Federal Prosecutors have gotten involved in the Cherif Traore racism case. And Bernard Laporte has set the date for his naming of his successor.

Give yourself an early Christmas present including over 40 hours of extra content when you sign up on Patreon! I'll even lie about you in the opening monologue! Pay for a year's membership and get 5% off!1641 was the year when Lennart Torstensson was finally appointed commander of Sweden's mostly German army. Having hunkered down for many years in the north of the country, Torstensson understood that Sweden had to strike hard against the Imperials if anything was to change. Possessed of a fierce determination and great strategic mind, the new commander pressed his advantage and seized a new triumph in the graveyard of Gustavus Adolphus' most famous victory. Torstensson knew a great deal about the Battle of Brietenfeld - he had commanded the artillery on that fateful day, and he intended to make this second Breitenfeld even greater than the first.Off the battlefield, peace feelers were finally beginning to go somewhere, albeit at a painfully slow pace. The basics of a two-city conference were established, but other than the selection of Osnabruck and Munster, little else of consequence could be decided on so long as there were victories to be gained from war. Still, these talks about peace talks produced significant fruit in their own right. The all out war was drawing to an end, and the interconnected fronts would soon be drawn into a peace. Before the peace was made, though, it would first have to be won.**DON'T FORGET TO FOLLOW THESE LINKS!**1) To support the podcast financially in return for some extra audio content, check out Patreon!2) To find a community of history friends, look at our Facebook page and group!3) To keep up to date with us, follow us on Twitter!4) Matchlock and the Embassy, our new historical fiction novel, is out NOW! Get it here5) Researcher? Student? Podcaster? Use Perlego to access a massive online library of books, and get a week for free! Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.